Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity.

LE Broker; FYFL de Vos; C.J. van Groeningen; B C Kuenen; HE Gall; MH Woo; M Voi; J.A. Gietema; E.G.E. de Vries; G. Giaccone

Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity.

LE Broker, FYFL de Vos, C.J. van Groeningen, B C Kuenen, HE Gall, MH Woo, M Voi, J.A. Gietema, E.G.E. de Vries, G. Giaccone

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Journal	Clinical Cancer Research
Volume	12
Issue number	6
Publication status	Published - Mar 2006

Cite this

@article{afcab61af2aa45108b8b19790efabf07,

title = "Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity.",

author = "LE Broker and {de Vos}, FYFL and {van Groeningen}, C.J. and Kuenen, {B C} and HE Gall and MH Woo and M Voi and J.A. Gietema and {de Vries}, E.G.E. and G. Giaccone",

year = "2006",

month = mar,

language = "English",

volume = "12",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "6",

}

TY - JOUR

T1 - Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity.

AU - Broker, LE

AU - de Vos, FYFL

AU - van Groeningen, C.J.

AU - Kuenen, B C

AU - Gall, HE

AU - Woo, MH

AU - Voi, M

AU - Gietema, J.A.

AU - de Vries, E.G.E.

AU - Giaccone, G.

PY - 2006/3

Y1 - 2006/3

M3 - Article

SN - 1078-0432

VL - 12

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 6

ER -